Replimune Group (REPL) Insider Trading & Ownership $10.95 +0.18 (+1.67%) (As of 11/19/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Replimune Group (NASDAQ:REPL) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.80%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)8Amount OfInsider Selling(Last 12 Months)$803,505.33 Get REPL Insider Trade Alerts Want to know when executives and insiders are buying or selling Replimune Group stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address REPL Insider Buying and Selling by Quarter Ad Porter & CompanyFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Replimune Group Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/16/2024Emily Luisa HillCFOSell8,938$10.18$90,988.84 6/7/2024Konstantinos XynosInsiderSell15,881$7.50$119,107.50 5/16/2024Andrew SchwendenmanCAOSell2,298$6.47$14,868.06 5/16/2024Christopher SarchiInsiderSell2,218$6.47$14,350.46 5/16/2024Colin LoveCOOSell17,615$6.47$113,969.05 5/16/2024Philip Astley-SparkeChairmanSell37,928$6.47$245,394.16 5/16/2024Robert CoffinDirectorSell11,464$6.47$74,172.08 5/16/2024Sushil PatelCEOSell20,194$6.47$130,655.18 (Data available from 1/1/2013 forward) REPL Insider Trading Activity - Frequently Asked Questions Who is on Replimune Group's Insider Roster? The list of insiders at Replimune Group includes Andrew Schwendenman, Christopher Sarchi, Colin Love, Emily Luisa Hill, Fund Iv L.P. Omega, Jean M Franchi, Konstantinos Xynos, Pamela Esposito, Philip Astley-Sparke, Robert Coffin, Sushil Patel, and Tanya Lewis. Learn more on insiders at REPL. What percentage of Replimune Group stock is owned by insiders? 8.80% of Replimune Group stock is owned by insiders. Learn more on REPL's insider holdings. Which Replimune Group insiders have been selling company stock? The following insiders have sold REPL shares in the last 24 months: Andrew Schwendenman ($14,868.06), Christopher Sarchi ($14,350.46), Colin Love ($308,457.80), Emily Luisa Hill ($90,988.84), Jean M Franchi ($204,885.55), Konstantinos Xynos ($198,965.46), Pamela Esposito ($1,314,449.58), Philip Astley-Sparke ($568,525.26), Robert Coffin ($74,172.08), Sushil Patel ($411,783.93), and Tanya Lewis ($309,411.60). How much insider selling is happening at Replimune Group? Insiders have sold a total of 252,670 Replimune Group shares in the last 24 months for a total of $3,510,858.62 sold. Replimune Group Key ExecutivesMr. Philip Astley-Sparke F.S.A. (Age 53)CEO & Director Compensation: $1.07MDr. Sushil Patel Ph.D. (Age 53)Chief Strategy Officer Compensation: $665.05kDr. Robert Coffin Ph.D. (Age 59)Founder, President, Chief Research & Development Officer and Director Compensation: $785.89kMs. Emily Luisa Hill (Age 44)Chief Financial Officer 1 recent tradesDr. Colin A. Love Ph.D. (Age 66)Chief Operating Officer Compensation: $419.37kMr. Andrew Schwendenman (Age 48)Chief Accounting Officer & Treasurer Dr. Pamela Esposito Ph.D. (Age 50)Chief Business Officer Compensation: $464.63kMs. Tanya N. Lewis M.S. (Age 53)Chief Development Operations Officer Compensation: $4.7kMr. Christopher Sarchi (Age 56)Chief Commercial Officer Dr. Konstantinos Xynos M.B.A. (Age 58)M.D., Ph.D., Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies Vir Biotechnology Insider Trades Atara Biotherapeutics Insider Trades AlloVir Insider Trades bluebird bio Insider Trades Beam Therapeutics Insider Trades Dyne Therapeutics Insider Trades Verona Pharma Insider Trades ACADIA Pharmaceuticals Insider Trades Kymera Therapeutics Insider Trades SpringWorks Therapeutics Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:REPL) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredThe Stock Powering Musk’s AI Revolution—RevealedImagine being able to invest in Tesla, PayPal, or SpaceX before the world knew their potential. Today, you ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
